These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25773947)

  • 1. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
    Kocakova I; Kocak I; Spelda S; Krejci E; Bencsikova B; Jureckova A; Vyzula R; Bortlicek Z; Strenkova J; Brabec P
    Bratisl Lek Listy; 2015; 116(4):218-21. PubMed ID: 25773947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
    Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.
    Hislop J; Mowatt G; Sharma P; Fraser C; Elders A; Jenkinson D; Vale L; Petty R
    J Gastrointest Cancer; 2012 Jun; 43(2):168-76. PubMed ID: 21971958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
    Rutkowski P; Magnan H; Chou AJ; Benson C
    BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
    Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
    Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
    Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
    Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
    Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
    Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
    Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    World J Surg Oncol; 2012 Jun; 10():111. PubMed ID: 22703877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
    Montemurro M; Schöffski P; Reichardt P; Gelderblom H; Schütte J; Hartmann JT; von Moos R; Seddon B; Joensuu H; Wendtner CM; Weber E; Grünwald V; Roth A; Leyvraz S
    Eur J Cancer; 2009 Sep; 45(13):2293-7. PubMed ID: 19467857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
    Contreras-Hernández I; Mould-Quevedo JF; Silva A; Salinas-Escudero G; Villasís-Keever MA; Granados-García V; Dávila-Loaiza G; Petersen JA; Garduño-Espinosa J
    Br J Cancer; 2008 Jun; 98(11):1762-8. PubMed ID: 18506179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
    Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of gastrointestinal stromal tumours.
    Judson I; Demetri G
    Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.